AR067823A1 - Compuestos de amina ciclica - Google Patents

Compuestos de amina ciclica

Info

Publication number
AR067823A1
AR067823A1 ARP080103428A ARP080103428A AR067823A1 AR 067823 A1 AR067823 A1 AR 067823A1 AR P080103428 A ARP080103428 A AR P080103428A AR P080103428 A ARP080103428 A AR P080103428A AR 067823 A1 AR067823 A1 AR 067823A1
Authority
AR
Argentina
Prior art keywords
group
atom
substituents
optionally
sulfur
Prior art date
Application number
ARP080103428A
Other languages
English (en)
Spanish (es)
Inventor
Atsushi Hasuoka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR067823A1 publication Critical patent/AR067823A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54Spiro-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
ARP080103428A 2007-08-07 2008-08-06 Compuestos de amina ciclica AR067823A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007205966 2007-08-07
JP2007299658 2007-11-19

Publications (1)

Publication Number Publication Date
AR067823A1 true AR067823A1 (es) 2009-10-21

Family

ID=40329363

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103428A AR067823A1 (es) 2007-08-07 2008-08-06 Compuestos de amina ciclica

Country Status (34)

Country Link
US (2) US7834051B2 (https=)
EP (1) EP2176220B1 (https=)
JP (1) JP5292390B2 (https=)
KR (1) KR20100049644A (https=)
CN (1) CN101821235B (https=)
AR (1) AR067823A1 (https=)
AU (1) AU2008284662B2 (https=)
BR (1) BRPI0814957B8 (https=)
CA (1) CA2695852C (https=)
CL (1) CL2008002313A1 (https=)
CO (1) CO6160326A2 (https=)
CR (1) CR11266A (https=)
CY (1) CY1114067T1 (https=)
DK (1) DK2176220T3 (https=)
DO (1) DOP2010000053A (https=)
EA (1) EA017429B1 (https=)
ES (1) ES2406685T3 (https=)
GE (1) GEP20125571B (https=)
HR (1) HRP20130374T1 (https=)
JO (1) JO2864B1 (https=)
MA (1) MA31639B1 (https=)
ME (1) ME01579B (https=)
MX (1) MX2010001484A (https=)
MY (1) MY159910A (https=)
NZ (1) NZ583624A (https=)
PE (1) PE20090899A1 (https=)
PL (1) PL2176220T3 (https=)
PT (1) PT2176220E (https=)
RS (1) RS52812B (https=)
SI (1) SI2176220T1 (https=)
TN (1) TN2010000062A1 (https=)
TW (1) TWI418543B (https=)
WO (1) WO2009020234A2 (https=)
ZA (1) ZA201001289B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2176220T3 (pl) * 2007-08-07 2013-08-30 Takeda Pharmaceuticals Co Pochodne pirolidyn-2-onu jako modulatory receptora androgenowego
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
ES2488990T3 (es) * 2008-02-22 2014-09-01 Radius Health, Inc. Moduladores selectivos del receptor de andrógenos
WO2009119880A1 (en) * 2008-03-26 2009-10-01 Takeda Pharmaceutical Company Limited Substituted pyrazole derivatives and use thereof
MX338831B (es) 2010-02-04 2016-05-03 Radius Health Inc Moduladores selectivos de receptores de androgenos.
EP2568806B1 (en) 2010-05-12 2016-05-11 Radius Health, Inc. Therapeutic regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
WO2013152170A1 (en) * 2012-04-04 2013-10-10 Catylix, Inc. Selective androgen receptor modulators
EP3378472A1 (en) 2012-08-09 2018-09-26 Dynamis Therapeutics, Inc. Combinations of meglumine
US9868905B2 (en) 2012-09-21 2018-01-16 Merck Patent Gmbh Compounds having a C—C triple bond and use thereof in liquid-crystal mixtures
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
FI3834824T3 (fi) 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
KR101597327B1 (ko) * 2014-04-24 2016-02-24 동아에스티 주식회사 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
CN103951688B (zh) * 2014-05-06 2016-04-20 成都安斯利生物医药有限公司 一种制备3,5-二氟-4-甲基苯硼酸的方法
LT3474841T (lt) 2016-06-22 2022-06-10 Ellipses Pharma Ltd Ar+ krūties vėžio gydymo būdai
KR102707399B1 (ko) 2017-01-05 2024-09-13 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
IL279853B2 (en) 2018-07-04 2025-01-01 Radius Pharmaceuticals Inc Polymorphic forms of RAD 1901-2HCL
JP7446316B2 (ja) 2019-01-11 2024-03-08 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換ピロリジンアミドiii
CN113348163B (zh) 2019-02-12 2024-10-08 雷迪厄斯制药公司 方法和化合物
CN110204505B (zh) * 2019-05-31 2023-02-03 荆门医药工业技术研究院 (s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺
US20230012570A1 (en) * 2019-11-20 2023-01-19 Medshine Discovery Inc. Bicyclic compound used as selective androgen receptor modulator

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4141399A1 (de) 1991-12-16 1993-06-17 Bayer Ag 4-(substituierte)amino-3-arylpyrrolinon-derivate
ES2300151T3 (es) * 1998-09-22 2008-06-01 Astellas Pharma Inc. Derivados de cianofenilo.
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7547728B2 (en) 2001-12-06 2009-06-16 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US7026500B2 (en) 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
JP2002088073A (ja) 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
FR2817472B1 (fr) 2000-12-06 2003-01-03 Oreal Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
EP1466902A4 (en) 2001-12-28 2005-11-09 Takeda Pharmaceutical ANTAGONISTS OF THE ANDROGEN RECEPTOR
JP4316232B2 (ja) 2001-12-28 2009-08-19 武田薬品工業株式会社 アンドロゲン受容体拮抗剤
GEP20074191B (en) 2002-06-17 2007-09-10 Univ Tennessee Res Foundation N-bridged selective androgen receptor modulators and methods of use thereof
BR0313405A (pt) 2002-08-12 2005-07-12 Takeda Pharmaceutical Compostos, métodos para preparar um composto e para prevenir e/ou tratar câncer, prodroga, medicamento, modulador do receptor de androgênio, agente para prevenir e/ou tratar hipogonadismo ou pertubação climatérica masculina, osteoporose e câncer, e, uso de um composto
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EP1747193A1 (en) * 2004-05-11 2007-01-31 Pfizer Products Incorporated Benzonitrile derivatives to treat musculoskeletal frailty
CA2566942A1 (en) 2004-05-17 2005-12-08 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
ATE552235T1 (de) 2004-06-07 2012-04-15 Univ Tennessee Res Foundation Selektive androgen-rezeptor-modulator und anwendungsverfahren dafür
NZ555974A (en) 2005-01-10 2010-11-26 Acadia Pharm Inc Aminophenyl derivatives as selective androgen receptor modulators
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
DK1891038T3 (da) 2005-05-13 2009-01-19 Lilly Co Eli Substituerede n-arylpyrrolidiner som selektive androgenreceptormodulatorer
EP1911743B8 (en) 2005-08-01 2013-01-16 Takeda Pharmaceutical Company Limited Cyclic amine compound
EP1987827A1 (en) 2006-02-20 2008-11-05 Takeda Pharmaceutical Company Limited Novel pharmaceutical
CA2658098A1 (en) * 2006-07-19 2008-01-24 Osurf Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
KR20090034395A (ko) 2006-07-26 2009-04-07 노파르티스 아게 운데카프레닐 피로포스페이트 합성효소의 억제제
CA2670976C (en) 2006-11-30 2015-01-27 Atsushi Hasuoka Cyclic amine compound
PL2176220T3 (pl) 2007-08-07 2013-08-30 Takeda Pharmaceuticals Co Pochodne pirolidyn-2-onu jako modulatory receptora androgenowego

Also Published As

Publication number Publication date
MA31639B1 (fr) 2010-08-02
CA2695852A1 (en) 2009-02-12
MX2010001484A (es) 2010-03-04
PT2176220E (pt) 2013-04-09
HK1143972A1 (en) 2011-01-21
JO2864B1 (en) 2015-03-15
CO6160326A2 (es) 2010-05-20
ME01579B (me) 2014-09-20
US20110098336A1 (en) 2011-04-28
JP2010535704A (ja) 2010-11-25
EP2176220A2 (en) 2010-04-21
KR20100049644A (ko) 2010-05-12
US8420694B2 (en) 2013-04-16
CR11266A (es) 2010-03-22
CA2695852C (en) 2017-01-03
NZ583624A (en) 2012-06-29
CY1114067T1 (el) 2016-07-27
CN101821235A (zh) 2010-09-01
PL2176220T3 (pl) 2013-08-30
EA201070246A1 (ru) 2010-08-30
TN2010000062A1 (en) 2011-09-26
BRPI0814957A2 (pt) 2015-02-03
SI2176220T1 (sl) 2013-05-31
WO2009020234A2 (en) 2009-02-12
ES2406685T3 (es) 2013-06-07
GEP20125571B (en) 2012-07-10
US20090042967A1 (en) 2009-02-12
EA017429B1 (ru) 2012-12-28
BRPI0814957B8 (pt) 2021-05-25
PE20090899A1 (es) 2009-08-06
EP2176220B1 (en) 2013-03-27
CN101821235B (zh) 2012-11-14
DK2176220T3 (da) 2013-06-10
BRPI0814957B1 (pt) 2019-12-03
ZA201001289B (en) 2011-04-28
TWI418543B (zh) 2013-12-11
DOP2010000053A (es) 2010-07-15
JP5292390B2 (ja) 2013-09-18
US7834051B2 (en) 2010-11-16
MY159910A (en) 2017-02-15
AU2008284662A1 (en) 2009-02-12
HRP20130374T1 (en) 2013-05-31
RS52812B (sr) 2013-10-31
AU2008284662B2 (en) 2013-07-25
WO2009020234A3 (en) 2009-04-16
CL2008002313A1 (es) 2009-05-15
TW200916439A (en) 2009-04-16

Similar Documents

Publication Publication Date Title
AR067823A1 (es) Compuestos de amina ciclica
DOP2010000068A (es) Derivados de pirazol sustituidos
PE20221083A1 (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
ES2506169T3 (es) Derivados de 5-fluoro-2-oxopirimidina-1(2H)-carboxilato como fungicidas
AR049784A1 (es) Derivados sustituidos de morfolina y tiomorfolina
MX343611B (es) Composicion de control de fitoenfermedades y su uso.
CY1119220T1 (el) Μονοκυκλικο παραγωγο πυριδινης
AR054130A1 (es) Procedimiento para la preparacion de 1-alquil-3-feniluracilos
MX2019006696A (es) Nuevos derivados de isoxazolil eter como moduladores alostericos positivos (pam) de acido gamma-aminobutirico (gaba) a alfa5.
AR073136A1 (es) Compuestos de pirrol
CO6210751A2 (es) Derivados de indolinona y procedimiento para su fabricacion
AR067691A1 (es) Derivados heterociclicos de sulfonimidoil, composiciones plaguicidas que los contienen y usos de los mismos para el control de plagas.
PE20211313A1 (es) Piperidinil-3-(ariloxi)propanamidas y propanoatos
ES2578628T3 (es) Compuestos de L-dihidro-2-oxoquinolina como ligandos del receptor de 5-HT4
AR078606A1 (es) Derivados de piperidina para prevenir y/o tratar trastornos degenerativos del sistema nervioso central
AR077176A1 (es) Derivado de piridina que contiene un anillo ((fosfonooxi) metil) piridinio y agente antifungico que contiene este derivado
MX2018011721A (es) Compuesto de griseofulvina.
CY1121626T1 (el) Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου
MX2015015010A (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.
PE20170245A1 (es) Pirazinas moduladoras de gpr 6
AR064306A1 (es) Antagonistas del receptor de angiotensina ii
CO2018003909A2 (es) Compuestos terapéuticos y sus métodos de uso
CO5700747A2 (es) Piperidinas novedosas como moduladores de quimoquina (ccr)
DOP2011000296A (es) Compuesto de pirazol
MX2015015058A (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.

Legal Events

Date Code Title Description
FB Suspension of granting procedure